This market will resolve to "Yes" if definitive evidence confirming that Donald Trump is currently or has recently (since January 1, 2024) been using Ozempic, Wegovy, or another GLP-1 receptor agonist primarily prescribed for weight loss or type 2 diabetes, is made public by June 30, 2025, 11:59 PM ET. Otherwise, this market will resolve to "No". Qualifying evidence includes but is not limited to public statements from Trump, a named personal physician, official medical records or other definitive evidence. Unverified or anonymous claims, or documents not substantiated by credible reporting will not qualify. The primary resolution source will be a consensus of credible reporting, and official information from Donald Trump.